Aspartate β-hydroxylase modulates cellular senescence through glycogen synthase kinase 3β in hepatocellular carcinoma

Hepatology

Volumn 63, Issue 4, 2016, Pages 1213-1226

  Iwagami, Yoshifumi ^a   Huang, Chiung Kuei ^a   Olsen, Mark J ^b   Thomas, John Michael ^b   Jang, Grace ^b   Kim, Miran ^a   Lin, Qiushi ^c   Carlson, Rolf I ^a   Wagner, Carl E ^d   Dong, Xiaoqun ^c   Wands, Jack R ^a  

^a Liver Research Center Brown University Medical School   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d ARIZONA STATE UNIVERSITY WEST   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARTATE BETA HYDROXYLASE; CYCLIN D1; CYCLINE; GLYCOGEN SYNTHASE KINASE 3BETA; MO I 1151; OXYGENASE; OXYGENASE INHIBITOR; PROTEIN KINASE B; PROTEIN P16; SHORT HAIRPIN RNA; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; ASPH PROTEIN, HUMAN; CALCIUM BINDING PROTEIN; GLYCOGEN SYNTHASE KINASE 3; GSK3B PROTEIN, HUMAN; GSK3B PROTEIN, MOUSE; MEMBRANE PROTEIN; MIXED FUNCTION OXIDASE; MUSCLE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER GROWTH; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COLONY FORMATION; CONTROLLED STUDY; CRISPR CAS SYSTEM; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SENESCENCE; ANIMAL; CELL AGING; DISEASE MODEL; ENZYMOLOGY; LIVER TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; RANDOMIZATION; SENSITIVITY AND SPECIFICITY; TUMOR CELL CULTURE; XENOGRAFT;

ANIMALS; CALCIUM-BINDING PROTEINS; CARCINOMA, HEPATOCELLULAR; CELL AGING; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HETEROGRAFTS; HUMANS; LIVER NEOPLASMS; MEMBRANE PROTEINS; MICE; MICE, NUDE; MIXED FUNCTION OXYGENASES; MUSCLE PROTEINS; PHOSPHORYLATION; RANDOM ALLOCATION; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 84959127115     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28411     Document Type: Article

References (44)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-543.
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-1127.
3. Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol 2013;10:34-42.
4. Jia S, VanDusen WJ, Diehl RE, Kohl NE, Dixon RA, Elliston KO, et al. cDNA cloning and expression of bovine aspartyl (asparaginyl) beta-hydroxylase. J Biol Chem 1992;267:14322-14327.
5. Engel J. EGF-like domains in extracellular matrix proteins: localized signals for growth and differentiation? FEBS Lett 1989;251:1-7.
6. Lavaissiere L, Jia S, Nishiyama M, de la Monte S, Stern AM, Wands JR, et al. Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma. J Clin Invest 1996;98:1313-1323.
7. Aihara A, Huang CK, Olsen MJ, Lin Q, Chung W, Tang Q, et al. A cell-surface beta-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma. Hepatology 2014;60:1302-1313.
8. Dong X, Lin Q, Aihara A, Li Y, Huang CK, Chung W, et al. Aspartate beta-hydroxylase expression promotes a malignant pancreatic cellular phenotype. Oncotarget 2015;6:1231-1248.
9. Sepe PS, Lahousse SA, Gemelli B, Chang H, Maeda T, Wands JR, et al. Role of the aspartyl-asparaginyl-beta-hydroxylase gene in neuroblastoma cell motility. Lab Invest 2002;82:881-891.
10. Luu M, Sabo E, de la Monte SM, Greaves W, Wang J, Tavares R, et al. Prognostic value of aspartyl (asparaginyl)-beta-hydroxylase/humbug expression in non-small cell lung carcinoma. Hum Pathol 2009;40:639-644.
11. Wang J, de la Monte SM, Sabo E, Kethu S, Tavares R, Branda M, et al. Prognostic value of humbug gene overexpression in stage II colon cancer. Hum Pathol 2007;38:17-25.
12. Ince N, de la Monte SM, Wands JR. Overexpression of human aspartyl (asparaginyl) beta-hydroxylase is associated with malignant transformation. Cancer Res 2000;60:1261-1266.
13. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965;37:614-636.
14. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007;8:729-740.
15. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
16. Campisi J. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol 2001;11:S27-S31.
17. Dimri GP. What has senescence got to do with cancer? Cancer Cell 2005;7:505-512.
18. Wiedenheft B, Sternberg SH, Doudna JA. RNA-guided genetic silencing systems in bacteria and archaea. Nature 2012;482:331-338.
19. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008;6:2853-2868.
20. Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 2010;5:99-118.
21. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Dev 2010;24:2463-2479.
22. Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001;2:769-776.
23. de la Monte SM, Tamaki S, Cantarini MC, Ince N, Wiedmann M, Carter JJ, et al. Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness. J Hepatol 2006;44:971-983.
24. Wang K, Liu J, Yan ZL, Li J, Shi LH, Cong WM, et al. Overexpression of aspartyl-(asparaginyl)-beta-hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome. Hepatology 2010;52:164-173.
25. Cantarini MC, de la Monte SM, Pang M, Tong M, D'Errico A, Trevisani F, et al. Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology 2006;44:446-457.
26. Gundogan F, Bedoya A, Gilligan J, Lau E, Mark P, De Paepe ME, et al. siRNA inhibition of aspartyl-asparaginyl beta-hydroxylase expression impairs cell motility, Notch signaling, and fetal growth. Pathol Res Pract 2011;207:545-553.
27. Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980;107:519-527.
28. Martinez A. Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs. Med Res Rev 2008;28:773-796.
29. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013;13:11-26.
30. Wands JR, Kim M. WNT/beta-catenin signaling and hepatocellular carcinoma. Hepatology 2014;60:452-454.
31. Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC, Cleary ML. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 2008;455:1205-1209.
32. Chen EY, DeRan MT, Ignatius MS, Grandinetti KB, Clagg R, McCarthy KM, et al. Glycogen synthase kinase 3 inhibitors induce the canonical WNT/beta-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma. Proc Natl Acad Sci USA 2014;111:5349-5354.
33. Mai W, Kawakami K, Shakoori A, Kyo S, Miyashita K, Yokoi K, et al. Deregulated GSK3β sustains gastrointestinal cancer cells survival by modulating human telomerase reverse transcriptase and telomerase. Clin Cancer Res 2009;15:6810-6819.
34. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12:3499-3511.
35. Cao Q, Lu X, Feng YJ. Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res 2006;16:671-677.
36. Favaro E, Bensaad K, Chong MG, Tennant DA, Ferguson DJ, Snell C, et al. Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. Cell Metab 2012;16:751-764.
37. Seo YH, Jung HJ, Shin HT, Kim YM, Yim H, Chung HY, et al. Enhanced glycogenesis is involved in cellular senescence via GSK3/GS modulation. Aging Cell 2008;7:894-907.
38. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995;92:9363-9367.
39. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell 2007;130:223-233.
40. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, et al. Tumour biology: senescence in premalignant tumours. Nature 2005;436:642.
41. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 2007;9:493-505.
42. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 2010;10:51-57.
43. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007;445:656-660.
44. Perez-Mancera PA, Young AR, Narita M. Inside and out: the activities of senescence in cancer. Nat Rev Cancer 2014;14:547-558.